Supplemental figure 1. Adjusted odds ratios (aOR) of COVID-19 mortality by previous exposure to chronic treatments (non-significant results).

ugs (ATC)	Exposed	Not exposed	aOR (95%CI)	
		No. of patients who died/total No. (%)		
parin group (B01AB)	6/12 (50.0%)	176/966 (18,2%)	3.12 (0.84 - 11.54))
licylic acid and derivatives (N02BA)	6/11 (54.5%)		3.00 (0.79 - 11.38)	
n bivalent, oral preparations (B03AA)	6/19 (31.6%)		2.79 (0.89 - 8.75)	
renergics in combination with corticosteroids or other drugs, excl. anticholinergics (R03AK)	7/20 (35.0%)		2.63 (0.90 - 7.70)	
ucocorticoids for sistemic use (H02AB)	7/12 (58.3%)		2.50 (0.67 - 9.32)	
renergics in combination with anticholinergics incl. triple combinations with corticosteroids (R03AL)	5/14 (35.7%)		2.04 (0.59 - 7.08)	1. The second se
her nasal preparations (R01AX)	16/35 (45.7%)		1.84 (0.81 - 4.16)	
orates (C10AB)	4/16 (25.0%)	178/962 (18.5%)	1.79 (0.50 - 6.41)	
lic acid and derivatives (B03BB)	10/32 (31.3%)	172/946 (18.2%)	1.64 (0.67 - 3.99)	
ect factor Xa inhibitors (B01AF)	19/40 (47.5%)	163/938 (17.4%)	1.63 (0.81 - 3.30)	
amin K antagonists (B01AA)	16/32 (50.0%)	166/946 (17.5%)	1.62 (0.73 - 3.62)	
her agents for local oral treatment (A01AD)	7/18 (38.9%)		1.61 (0.56 - 4.61)	
ugs for urinary frequency and incontinence (G04BD)	6/18 (33.3%)		1.56 (0.53 - 4.55)	2
ilides (N02BE)			1.46 (0.93 - 2.29)	
her antiepileptics (N03AX)	23/71 (32.4%)		1.44 (0.80 - 2.61)	
oton pump inhibitors (A02BC)			1.40 (0.95 - 2.06)	
giotensin II receptor blockers (ARBs), plain (C09CA)			1.38 (0.86 - 2.20)	
n in combination with folic acid (B03AD)	7/16 (43.8%)		1.38 (0.42 - 4.47)	
nydropyridine derivatives (C08CA)	42/118 (35.6%)		1.37 (0.83 - 2.24)	
sphosphonates (M05BA)	6/21 (28.6%)		1.36 (0.48 - 3.83)	
her antidepressants (N06AX)	21/67 (31.3%)	161/911 (17.7%)	1.28 (0.69 - 2.35)	
n-selective monoamine reuptake inhibitors (N06AA)	5/20 (25.0%)	177/958 (18.5%)	1.27 (0.39 - 4.13)	
perazine derivatives (R06AE)	4/12 (33.3%)	178/966 (18.4%)	1.26 (0.31 - 5.08)	
motically acting laxatives (A06AD)	7/19 (36.8%)		1.16 (0.40 - 3.41)	
lective beta-2-adrenoreceptor agonists (R03AC)	16/47 (34.0%)		1.16 (0.57 - 2.35)	
rticosteroids acting locally (A07EA)	24/80 (30.0%)		1.15 (0.64 - 2.09)	
IG CoA reductase inhibitors (C10AA)	73/248 (29.4%)		1.14 (0.76 - 1.70)	
iazides, plain (C03AA)	16/62 (25.8%)		1.12 (0.59 - 2.15)	
E inhibitors, plain (C09AA)	52/171 (30.4%)		1.11 (0.71 - 1.73)	
ta blocking agents, selective (C07AB)	37/116 (31.9%)		1.04 (0.64 - 1.69)	
ticholinergics (R03BB)	17/43 (39.5%)		1.03 (0.50 - 2.13)	·•
lective beta-2-adrenoreceptor agonists (R03CC)	10/38 (26.3%)	172/940 (18.3%)	1.01 (0.41 - 2.47)	•
nzodiazepine derivatives (hypnotics and sedatives) (N05CD)	10/34 (29.4%)	172/944 (18.2%)	1.00 (0.43 - 2.30)	e
eparations inhibiting uric acid production (M04AA)	15/55 (27.3%)	167/923 (18.1%)	0.95 (0.45 - 1.99)	
Ifonamides, plain (C03CA)	40/105 (38.1%)	142/873 (16.3%)	0.94 (0.57 - 1.55)	· · · · · · · · · · · · · · · · · · ·
amin D and analogues (A11CC)	23/83 (27.7%)	159/895 (17.8%)		e
peptidyl peptidase 4 (DPP-4) inhibitors (A10BH)	15/56 (26.8%)		0.89 (0.42 - 1.87)	
bha-adrenoreceptor antagonists (G04CA)	23/67 (34.3%)		0.85 (0.45 - 1.58)	
atelet aggregation inhibitors excl. heparin (B01AC)	41/129 (31.8%)	141/849 (16.6%)		-
yroid hormones (H03AA)	9/58 (15.5%)	173/920 (18.8%)		
oha and beta blocking agents (C07AG)	7/25 (28.0%)		0.79 (0.29 - 2.14)	75
ioids (N02A-)	15/58 (25.9%)		0.78 (0.39 - 1.54)	
stosterone-5-alpha reductase inhibitors (G04CB)	4/13 (30.8%)	178/965 (18.4%)		
lective serotonin reuptake inhibitors (N06AB)	20/93 (21.5%)	162/885 (18.3%)	0.72 (0.40 - 1.29)	· · · · · · · · · · · · · · · · · · ·
Ifonylureas (A10BB)	3/22 (13.6%)	179/956 (18.7%)	0.71 (0.18 - 2.81)	· · · · · · · · · · · · · · · · · · ·
her cardiac preparations (C01EB)	4/12 (33.3%)	178/966 (18.4%)	0.69 (0.17 - 2.83)	
ganic nitrates (C01DA)	8/23 (34.8%)	174/955 (18.2%)	0.69 (0.26 - 1.83)	2 <u></u>
her antipsychotics (N05AX)	4/18 (22.2%)		0.66 (0.17 - 2.52)	
razolones (N02BB)	9/38 (23.7%)		0.64 (0.28 - 1.46)	
bha-adrenoreceptor antagonists (C02CA)	5/20 (25.0%)	177/958 (18.5%)		
amin B12 (cyanocobalamin and analogues) (B03BA)	4/14 (28.6%)	178/964 (18.5%)		
guanides (A10BA)	25/115 (21.7%)		0.57 (0.28 - 1.16)	
nzamides (N05AL)	2/11 (18.2%)	180/967 (18.6%)		
azepines, oxazepines, thiazepines and oxepines (N05AH)	10/45 (22.2%)	172/933 (18.4%)		
ticholinesterases (N06DA)	3/14 (21.4%)	179/964 (18.6%)	0.43 (0.11 - 1.69)	
ta blocking agents, non-selective (C07AA)	2/13 (15.4%)		0.35 (0.07 - 1.80)	<
her antihistamines for systemic use (R06AX)	1/19 (5.3%)		0.29 (0.04 - 2.42)	